Comparison of Effects of EBV-DNA on IMRT and DW-MRI Guided SIB-IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase II Randomised Controlled Trial

Conditions

nasopharyngeal carcinoma

Fu S, Li Y, Han Y, Wang H, Chen Y, Yan O, He Q, Ma H, Liu L, Liu F.

2022-01-2226 citations

10.1016/j.ijrobp.2021.12.175

A Randomized Controlled Trial of Reirradiation Using Diffusion-Weighted MRI Guided Dose-Painting vs. CT-Based Radiotherapy for Locally Recurrent T3 to T4 Nasopharyngeal Carcinoma.

Liu F, Fu SN, Chen YZ, Yan OY, Jiang C, Wu X, Han YQ, Wang H.

2021-11-01

10.1016/j.ijrobp.2021.07.159

A randomized phase II trial of diffusion-weighted MR imaging-guided radiotherapy plus chemotherapy versus standard chemoradiotherapy in locoregional advanced nasopharyngeal carcinoma.

Feng Liu, Shengnan Fu, Yanzhu Chen, Ouying Yan, Lili He et al. (9 authors)

Journal of Clinical Oncology2021-05-203 citations

10.1200/jco.2021.39.15_suppl.6018

Interventions

group B (DW-MRI guided SIB-IMRT group):diffusion weighted magnetic Resonance Imaging (DW-MRT) guided simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT)

group A (control group):anatomical image-based intensity-modulated radiation therapy (IMRT)

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Eligible patients will be 18 to 70 years ages with non-distant metastatic, histologically proven WHO types II-III, stage T3-4N0-3M0 nasopharyngeal carcinoma (8th Union for International Cancer Control, UICC). All participants have Karnofsky scores of at least 70, and adequate bone marrow (leukocyte count =4.0×109/L, absolute neutrophil count =1.5×10^9/L, platelets =100×10^9/L), liver, and renal functions. Patients are required to provide written informed consent before undergoing chemoradiotherapy.

Exclusion criteria

Exclusion criteria: Patients with history of previous radiotherapy, secondary malignancy, evidence of distant metastasis, pregnancy or lactation are excluded from the study.

Design outcomes

Primary

Measure	Time frame
overall survival (OS);	—

Secondary

Measure	Time frame
disease-free survival (DFS);distant metastasis-free survival (DMFS);local recurrence-free survival (LRFS);regional recurrence-free survival;loco-regional recurrence-free survival (LRRFS);response rates;toxic effects;	—

Countries

China

Contacts

Public ContactLiu Feng

Department of Radiation Oncology, Hunan Cancer Hospital

liufeng820111@163.com+86 18613985727

Outcome results

None listed